adoptive immunotherapy

Phase 3Cell therapy

MM.D. Anderson Cancer Center

adoptive immunotherapy is one of 31 biologic programs targeting Hepatocellular Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaRecruiting

Hepatocellular CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

adoptive immunotherapy

MM.D. Anderson Cancer Center

Phase 3

1 2

Ibrance

Pfizer

Preclinical

1 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Hepsera

Doptelet

1 6

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 7

Vermox

WWim Janssens

Preclinical

1 8

Valemetostat

Bristol-Myers Squibb

Preclinical

1 9

Alcohol

Astellas

Preclinical

—10

Anti-PD-1 Monoclonal Antibody

IiTeos Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Hepatocellular Carcinoma

NCT02851784

Clinical

Trials by Indication[1]

Metastatic Melanoma1 trial

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Completed·PProf. Serge Leyvraz·Phase 1·NCT00324623·8 enrolled

Psoriasis1 trial

Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis

Completed·—·Phase 1/2·NCT01894373·10 enrolled

Cytomegalovirus Infection1 trial

T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

Unknown status·UUniversity Hospital Birmingham·Phase 2·NCT00986557·78 enrolled

Gastrointestinal Tumors1 trial

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02757391·1 enrolled

Hepatocellular Carcinoma1 trial

Combination Therapy of Microwave Ablation and Expanding Activated Autologous Lymphocytes for Hepatocellular Carcinoma

Recruiting·CChinese PLA General Hospital·Preclinical·NCT02851784·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for adoptive immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — adoptive immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for adoptive immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: MM.D. Anderson Cancer Center

adoptive immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Metastatic Melanoma1 trial

Psoriasis1 trial

Cytomegalovirus Infection1 trial

Gastrointestinal Tumors1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News